Free Trial
NASDAQ:GYRE

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Gyre Therapeutics logo
$7.20 +0.18 (+2.56%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$7.35 +0.15 (+2.08%)
As of 08/7/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gyre Therapeutics Stock (NASDAQ:GYRE)

Key Stats

Today's Range
$7.02
$7.47
50-Day Range
$6.65
$9.10
52-Week Range
$6.11
$19.00
Volume
103,870 shs
Average Volume
76,865 shs
Market Capitalization
$675.07 million
P/E Ratio
360.18
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Gyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
0th Percentile Overall Score

GYRE MarketRank™: 

Gyre Therapeutics scored higher than 0% of companies evaluated by MarketBeat, and ranked 921st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gyre Therapeutics is 360.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gyre Therapeutics is 360.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Book Value per Share Ratio

    Gyre Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gyre Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.13% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Gyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gyre Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.13% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Gyre Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,804.00 in company stock.

  • Percentage Held by Insiders

    Only 10.00% of the stock of Gyre Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

  • Read more about Gyre Therapeutics' insider trading history.
Receive GYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GYRE Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Headlines

GYRE Stock Analysis - Frequently Asked Questions

Gyre Therapeutics' stock was trading at $12.10 at the beginning of 2025. Since then, GYRE stock has decreased by 40.5% and is now trading at $7.20.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings results on Friday, May, 9th. The company reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The firm earned $22.06 million during the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a net margin of 7.20% and a trailing twelve-month return on equity of 9.73%.

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/09/2025
Today
8/07/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GYRE
Previous Symbol
NASDAQ:GYRE
CIK
1124105
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.02
Trailing P/E Ratio
360.18
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.09 million
Net Margins
7.20%
Pretax Margin
15.27%
Return on Equity
9.73%
Return on Assets
7.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.60
Quick Ratio
3.19

Sales & Book Value

Annual Sales
$105.76 million
Price / Sales
6.38
Cash Flow
$0.21 per share
Price / Cash Flow
35.04
Book Value
$1.05 per share
Price / Book
6.86

Miscellaneous

Outstanding Shares
93,760,000
Free Float
84,382,000
Market Cap
$675.07 million
Optionable
No Data
Beta
1.80
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:GYRE) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners